- Home
- CKPT vs SATX Comparison
CKPT vs SATX Comparison
Compare CKPT & SATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- SATX
- Stock Information
- Founded
- CKPT 2014
- SATX 2012
- Country
- CKPT United States
- SATX Israel
- Employees
- CKPT N/A
- SATX N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- SATX Radio And Television Broadcasting And Communications Equipment
- Sector
- CKPT Health Care
- SATX Technology
- Exchange
- CKPT Nasdaq
- SATX Nasdaq
- Market Cap
- CKPT 151.9M
- SATX 130.6M
- IPO Year
- CKPT 2017
- SATX N/A
- Fundamental
- Price
- CKPT $3.00
- SATX $1.44
- Analyst Decision
- CKPT Strong Buy
- SATX Strong Buy
- Analyst Count
- CKPT 2
- SATX 2
- Target Price
- CKPT $13.50
- SATX $2.25
- AVG Volume (30 Days)
- CKPT 998.1K
- SATX 461.3K
- Earning Date
- CKPT 11-12-2024
- SATX 02-14-2025
- Dividend Yield
- CKPT N/A
- SATX N/A
- EPS Growth
- CKPT N/A
- SATX N/A
- EPS
- CKPT N/A
- SATX N/A
- Revenue
- CKPT $47,000.00
- SATX $10,351,000.00
- Revenue This Year
- CKPT N/A
- SATX $80.62
- Revenue Next Year
- CKPT $172,016.02
- SATX N/A
- P/E Ratio
- CKPT N/A
- SATX N/A
- Revenue Growth
- CKPT N/A
- SATX N/A
- 52 Week Low
- CKPT $1.38
- SATX $0.33
- 52 Week High
- CKPT $4.50
- SATX $2.39
- Technical
- Relative Strength Index (RSI)
- CKPT 38.29
- SATX 52.89
- Support Level
- CKPT $3.07
- SATX $1.21
- Resistance Level
- CKPT $3.42
- SATX $1.57
- Average True Range (ATR)
- CKPT 0.21
- SATX 0.33
- MACD
- CKPT -0.03
- SATX -0.04
- Stochastic Oscillator
- CKPT 4.94
- SATX 19.63
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About SATX SatixFy Communications Ltd.
SatixFy Communications Ltd develops end-to-end next-generation satellite communications systems, including satellite payloads, user terminals and modems, based on powerful chipsets that it develops in house. Its products include modems that feature Software Defined Radio and Fully Electronically Steered Multi Beam Antennas that support the advanced communications standard DVB-S2X. Geographical presence in U.S, Canada, UK and Other countries. Majority of its company revenue comes from U.S and Canada.